Editorially Independent content supported with advertising by Genentech
Joseph M. Coney, MD
Show Description +
Joseph M. Coney, MD, presents the case of a patient with bilateral DME whose disease has been present for over a decade and is responsive to anti-VEGF treatment—but who is unable to extend beyond monthly treatment. After 52 injections of aflibercept 2 mg (Eylea, Regeneron) over the course of his disease, the patient responds well to faricimab (Vabysmo, Genentech/Roche) therapy and a slightly extended interval. What approaches would Priya Sharma Vakharia, MD, and Yasha S. Modi, MD, take moving forward with this patient?
Posted: 1/15/2024
Joseph M. Coney, MD
Joseph M. Coney, MD, presents the case of a patient with bilateral DME whose disease has been present for over a decade and is responsive to anti-VEGF treatment—but who is unable to extend beyond monthly treatment. After 52 injections of aflibercept 2 mg (Eylea, Regeneron) over the course of his disease, the patient responds well to faricimab (Vabysmo, Genentech/Roche) therapy and a slightly extended interval. What approaches would Priya Sharma Vakharia, MD, and Yasha S. Modi, MD, take moving forward with this patient?
Posted: 1/15/2024
Please log in to leave a comment.